▶ Full Post Text
Hello everyone, I wanted to share my DD about $CJMB since it may be a great opportunity and a deep value play at these prices. Insiders are holding almost 75 PORCENTAJE of the company and the float is about \~1M shares with a \~$5M market cap.
**Callan JMB ($CJMB)** operates logistics infrastructure focused on cold chain, regulated materiales handling, and emergency preparedness. It’s trading near historical lows, despite expanding its operational footprint and seeing massive insider conviction.
They focus on services that are essential for life sciences, vaccines, cell therapy, pharma and temperature sensitive supply chains.
https://preview.redd.it/qebhneg6twcg1.png?width=659&format=png&auto=webp&s=f7a46da0020c9ba816f5dda23826b17bbe31d38a
**Valuation floor. A net-net discrepancy**
$CJMB is currently trading at a $5.2M market cap, but if we look at the balance sheet:
\- Cash: $4.2M
\- Enterprise value (EV): \~$1M
\- Revenue: they recently secured an extension for their City of Chicago emergency supplies contract through June 2026, increasing total contract value to $9.1M
**With this, it basically looks like you are buying a company with nearly $10M in contract backing and $4M in cash for a $1M “business value”.**
**Insider conviction**
One of the most bullish signals I found was the CEO Wayne D. Williams, and other company directors, bought the stock in December 2025 at prices significantly higher than today.
CEO and Directors purchases: buys at $1.65, $1.70 and $1.75 in December. I kow this doesn’t necessarily mean anything, but it’s always good that insiders keep buying. It may be a signal of some near term catalysts? We can’t know, but it’s still positive.
**At this point ($1.15), we are buying at a 33 PORCENTAJE discount to the CEO’s personal entry point, and over 80 porcentaje below the 52-week high of $7.76.**
**Business pivot, not just traditional logistics.**
$CJMB is actually becoming a high margins pharma support hub.
1. Texas Manufacturing Facility: a preliminary agreement is in place to host oral drug delivery manufacturing equipment. This moves CJMB up the value chain, from moving boxes to manufacturing support.
2. Food Sampling Logistics: diversifying revenue streams by entering the high volume food logistics market, ensuring they don’t depend on a single sector (their pharma transport sector is still the most profitable one).
3. Governance Overhaul: the board recently updated insider trading policies to align with top tier financial reporting standards. This normally happens right before a company prepares for significant growth, or even a strategic buyout. Who knows.
**The GLP-1 (Ozempic) bottleneck**
The global healthcare theme of 2025-2026 is GLP-1 (Ozempic, weight loss drugs). These drugs are peptides that require strict **cold chain management (2°C to 8°C).**
CJMB specializes in regulated cold chain and thermal packaging. As pharmacies and telehealth providers struggle with GLP-1 distribution, niche players like CJMB become the essential infrastructure. In my opinion, this is the main catalyst the market hasn’t priced in yet.
https://preview.redd.it/lhmc3t7dtwcg1.png?width=484&format=png&auto=webp&s=4fe71dc54a5881d7a2a0166b9a54986100e7d7ce
https://preview.redd.it/zfsjr2udtwcg1.png?width=484&format=png&auto=webp&s=042bd7ee89b4b1a1b7b162f7ccae972549bb7f57
**About the technicals**
\- **Free float:** \~1.2M shares
\- **Insider ownership:** 73.8 porcentaje
\- **Market cap:** $5.2M
Obviously, with insiders holding almost ¾ of the company, and the float being so small, it only takes a spark of volume to cause a parabolic run, making the ask side vanish instantly.
**The most important catalysts to look at**
* Inmediate: the operational updates they are getting regarding the Texas equipment deployment (contract worth almost $10M)
* Feb 11, 2026: quarterly earnings. Expectations are pretty low to be honest, but making any revenue beat or margin improvement could bring huge volatility.
* Spring 2026: potential strategic partnership season, with possible M&A news about a bigger logistics player who wants to expand to pharma logistics.
**M&A scenarios and why I think a buyout will end up being inevitable**
Well, the logistics sector is currently undergoing a massive consolidation phase. Giants like UPS, FedEx and DHL are racing to increase their healthcare revenue by 2026, and they are doing it mostly by buying specialized companies.
Here is where GLP-1 and $CJMB play an important role. With the Ozempic boom, the demand for 2°C–8°C cold chain capacity has outpaced supply. For a bigger player in the industry, buying CJMB at a $20M–$30M valuation is a gift. This acquisition, would literally buy them instant infrastructure, proprietary thermal packaging, and a strategic Texas hub. 3 companies of which I think have the most chances to buy CJMB (AI has helped me here):
**1. UPS with their healthcare expansion (Highest probability)**
UPS recently acquired Andlauer Healthcare Group for $1.6B to dominate the North American cold chain. Their goal is $20B in healthcare revenue by 2026.
CJMB’s niche in thermal packaging and specialized Texas fulfillment is a perfect bolt on acquisition to fill their mid market capacity gaps.
**2. Cencora (formerly AmerisourceBergen) vertical play**
Cencora is investing $1B into its US distribution network. They are moving away from being just "distributors" to owning the entire supply chain.
CJMB’s government contracts (Chicago) and pharma-grade warehousing make it an attractive target to strengthen Cencora’s "last-mile" delivery of specialty medications.
**3. Cryoport**
Cryoport is the leader in ultra-cold (cryogenic) logistics. However, they need to expand into the much larger "standard" refrigerated market (2-8°C) where GLP-1 drugs live. Buying CJMB allows Cryoport to immediately capture the "Ozempic logistics" market share without building the technology from scratch.
**Some basic M&A math:**
\- EV is currently $1M
\- Most niche logistics firms sell for 1.5x to 2x revenue
\- Target buyout price: **$3.50 to $5.00 per share.**
As soon as a buyout offer hits, the gap from **$1.15 to $4.00** closes in literally 5 minutes.
**My price targets considering no buyout**
\- **(1-2 weeks): $1.80 - $2.50.** A simple gap fill to the CEO’s buy price (+60 porcentaje to +100 porcentaje)
\- **(4-5 weeks): $3.00 - $4.20.** If revenue beats or they confirm GLP-1 contract wins (+160 porcentaje to +260 porcentaje).
**My final conclusions**
I see $CJMB as a deep value play disguised as a boring logistics company. It’s obviously a long term play, but any contract news will bring this up in the near term. With cash backing, government contracts, and heavy insider buying at $1.73, the downside is protected by a concrete floor. Meanwhile, the upside is an uncapped ceiling driven by the most explosive sector in pharma today.